ストックスクリーナーアプリを入手
2.565
1.73%
-0.035
前日終値:
$2.60
開ける：
$2.61
24時間の取引高:
33,532
Relative Volume:
0.02
時価総額：
$347.09M
収益：
-
当期純損益:
$-45.44M
株価収益率:
-7.3286
EPS:
-0.35
ネットキャッシュフロー:
$-42.28M
1週間 パフォーマンス:
+6.46%
1か月 パフォーマンス:
+21.09%
6か月 パフォーマンス:
+75.00%
1年 パフォーマンス:
+112.92%
1日の値動き範囲:
$2.54
$2.61
1週間の範囲:
$2.32
$2.76
52週間の値動き範囲:
$0.765
$4.08
Compass Therapeutics Inc Stock (CMPX) Company Profile
CMPX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
2.565 | 347.09M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.83 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.18 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.11 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
562.38 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.31 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-02 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | 開始されました | Guggenheim | Buy |
| 2025-02-19 | 開始されました | Piper Sandler | Overweight |
| 2024-12-23 | 開始されました | D. Boral Capital | Buy |
| 2024-11-15 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | 開始されました | Jefferies | Buy |
| 2023-01-27 | 開始されました | Stifel | Buy |
| 2022-05-23 | 再開されました | H.C. Wainwright | Buy |
| 2022-03-15 | 開始されました | Ladenburg Thalmann | Buy |
| 2022-01-19 | 開始されました | B. Riley Securities | Buy |
| 2021-12-22 | 開始されました | Raymond James | Outperform |
| 2021-12-20 | 開始されました | SVB Leerink | Outperform |
| 2021-12-15 | 開始されました | Wedbush | Outperform |
すべてを表示
Compass Therapeutics Inc (CMPX) 最新ニュース
PD-1 and PD-L1 Inhibitors Competitor Landscape Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Compass Therapeutics, Aurigene Discovery Tech - The Globe and Mail
SG Americas Securities LLC Buys 545,767 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Acquired by Bank of America Corp DE - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Millennium Management LLC - Defense World
Two Sigma Investments LP Sells 48,021 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics Confirms Directors at Annual Meeting - TipRanks
Cholangiocarcinoma Market Booming Worldwide, Estimated to Reach USD 2,334.4 Mn by 2032 | Incyte CorporationSOUTHEAST - SOUTHEAST - NEWS CHANNEL NEBRASKA
Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Squarepoint Ops LLC Acquires New Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
CMPX to Participate in Virtual Meeting Hosted by Piper Sandler | - GuruFocus
CMPX to Participate in Virtual Meeting Hosted by Piper Sandler | CMPX Stock News - GuruFocus
Two Sigma Advisers LP Cuts Stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Transition Metals (CVE:XTM) Shares Up 62.5% – Time to Buy? - Defense World
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Purchased by Two Sigma Advisers LP - Defense World
BNP Paribas Financial Markets Makes New $27,000 Investment in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
ProShare Advisors LLC Has $42,000 Position in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Northern Trust Corp Sells 43,164 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics, Inc. (CMPX) Stock Analysis: A Biotech Gem with Over 500% Potential Upside - DirectorsTalk Interviews
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
Insider Buying: Thomas Schuetz Acquires Additional Shares of Com - GuruFocus
Compass Therapeutics CEO acquires $21,100 in common stock - Investing.com Australia
Compass Therapeutics CEO acquires $21,100 in common stock By Investing.com - Investing.com India
Compass Therapeutics CEO Acquires 10,000 Shares - TradingView
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Rating of “Buy” from Brokerages - Defense World
Dimensional Fund Advisors LP Buys New Stake in Babcock & Wilcox Enterprises, Inc. (NYSE:BW) - Defense World
Bell Investment Advisors Inc Buys 79 Shares of Apple Inc. (NASDAQ:AAPL) - Defense World
Dark Forest Capital Management LP Cuts Stock Holdings in NVIDIA Co. (NASDAQ:NVDA) - Defense World
Price T Rowe Associates Inc. MD Increases Holdings in Absci Co. (NASDAQ:ABSI) - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Bought by Price T Rowe Associates Inc. MD - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Purchased by Price T Rowe Associates Inc. MD - Defense World
Ceera Investments LLC Grows Stock Position in Apple Inc. (NASDAQ:AAPL) - Defense World
Apple Inc. (NASDAQ:AAPL) is Sound View Wealth Advisors Group LLC’s Largest Position - Defense World
Frontier Asset Management LLC Acquires 1,041 Shares of Apple Inc. (NASDAQ:AAPL) - Defense World
Rebalance LLC Grows Stake in Apple Inc. (NASDAQ:AAPL) - Defense World
Ocugen, Inc. (NASDAQ:OCGN) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Voya Investment Management LLC Sells 5,102 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Spotlight On Three Promising Penny Stocks In May 2025 - Yahoo Finance
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Wells Fargo & Company MN - Defense World
Wells Fargo & Company MN Acquires 13,038 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers - Seeking Alpha
Guggenheim Cuts Compass Therapeutics (NASDAQ:CMPX) Price Target to $10.00 - Defense World
Barclays PLC Has $279,000 Stock Position in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Mariner LLC Purchases New Stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Guggenheim Adjusts Price Target for Compass Therapeutics (CMPX) - GuruFocus
Compass Therapeutics (CMPX) Price Target Lowered by Guggenheim | CMPX Stock News - GuruFocus
Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update - GlobeNewswire
Compass Therapeutics Reports Q1 2025 Financial Results - TipRanks
Compass Therapeutics, Inc. SEC 10-Q Report - TradingView
Compass Therapeutics to Participate in Upcoming May Investor Events - GlobeNewswire
Renaissance Technologies LLC Grows Stock Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Cholangiocarcinoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - Barchart.com
Compass Therapeutics Inc (CMPX) 財務データ
収益
当期純利益
現金流量
EPS
Compass Therapeutics Inc (CMPX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| GORDON CARL L | Director |
Apr 09 '25 |
Sale |
1.59 |
3,571,428 |
5,678,571 |
0 |
| ORBIMED ADVISORS LLC | Director |
Apr 09 '25 |
Sale |
1.59 |
3,571,428 |
5,678,571 |
0 |
1.37%
0.65%
大文字化:
|
ボリューム (24 時間):